



# New Technologies for Vaccine Development: Harnessing the Power of Human Immunology

Anmol Chandele\* 

**Abstract** | Our understanding of human immune responses is increasing at an unprecedented scale. Cutting edge new technologies are allowing us to disregard a piecemeal approach and analyze human immune responses in a comprehensive and cohesive manner. Innovative approaches to analyze immune cell phenotype, genotype, function, and associated soluble factors have provided us with a new hope for making vaccines against diseases that have been historically impossible. This review recaps a few state-of-the-art tools and technologies that have helped us harness the power of human immunology for vaccine design, evaluation, and testing.

## 1 Introduction

Vaccines are the most successful, cost-effective tools to prevent or significantly reduce the incidence of disease and mortality.<sup>1</sup> However, many infections that have complex host–pathogen interactions are still not vaccine preventable and continue to cause high morbidity and mortality in both India and worldwide.

Since the advent of mankind, life-long immunity against communicable diseases was achieved empirically. One of the first historical written documentation of such empirically acquired immunity to infectious disease is recorded in the description of the plague that devastated the city–state of Athens, Greece in 430 bce, killing one-third of its population. However, it was observed at that time that individuals who survived the plague never suffered from it again, which indicated to the concept of life-long immunity after exposure.<sup>2</sup> This practice of prophylactically exposing healthy individuals to natural infections was continued until about the 1950s what was known as ‘measles parties’, where in healthy children are invited to the house, where a child has measles to increase probability of exposure.<sup>3</sup>

Even before Edward Jenner’s landmark discovery of ‘vaccination’ with cowpox in 1796, the first reports of immunization for small pox date are as far back as the tenth century China.<sup>4</sup> Pus-tules from individuals with mild small pox were dried and nasally administered to uninfected

individuals or inoculated into the skin through variolation. This was also likely customary in Africa, India and Central Asia long before it was introduced in Europe from Istanbul in 1714 by Emanuel Timoni and Giacomo Pilarino through separate but simultaneous letters to the Royal Society of London.<sup>5</sup> The earliest reports of variolation of an individual of European decent comes from Lady Montague who decided to inoculate her 5-year-old son in 1718 in Istanbul, followed by her 4-year-old daughter upon her return to London in 1721.<sup>5</sup>

However, this process of variolation not only caused very severe disease manifestations, but also resulted in Death of some individuals. Thus, Jenner’s revolutionary observation that milkmaids that handled cows with similar small pox like lesions did not suffer from the perils of the deadly disease, laid the foundation for the use of an attenuated pathogens to provide long-term protective immunity. Therefore, this hallmark experiment is considered to be the official birth of vaccines and vaccinations, which lead to the ultimate global eradication of the deadly small pox in 1980.<sup>6</sup>

Through the years, Louis Pasteur who developed the first rabies vaccine in 1885<sup>7</sup> then refined Edward Jenner’s work that resulted in the first generation of vaccines, which were based on, attenuated or killed pathogens (e.g., BCG; plague; pertussis, etc.). These innovations were then

International Center  
for Genetic Engineering  
and Biotechnology, New  
Delhi, India  
\*anmol@icgeb.res.in

closely followed by the use of live attenuated strains to make vaccines such as the Sabin oral polio, Hepatitis A and MMR and are categorized as the second generation of vaccines. The discovery and use of these traditional vaccines that are listed in Table 1 have saved millions of lives and decreased morbidity over the last century (<http://www.who.int/immunization/diseases/en/>).

Unfortunately, these traditional methods have proven ineffective for pathogens that have complex host–parasite interactions (dengue/chikungunya/influenza), establish chronic infection (TB) or pathogens that cannot be cultured in vitro such as *Mycobacterium leprae*. Moreover, increasing number of host-related issues such as having an immature immune system such as during infancy,<sup>8</sup> aging,<sup>9</sup> non-communicable diseases that affect immune responses such as diabetes,<sup>10</sup> etc. further add to challenges in vaccine design and development. A few of them are listed in Table 2 that allow us to appreciate the hurdles that need to be overcome for any new vaccine.

Moreover, most successful vaccines to date heavily rely on the generating a high titer antibody response. With progress in vaccine research, it is becoming more evident, that an antibody-based vaccine alone cannot overcome diseases that fall into the spectrum of having complex host–parasite interphases. In fact, going back to some of the most successful vaccines and comprehensively analyzing both arms of the adaptive immune response (humoral and cell mediated), we have come to realize that though empirically, only antibody titers were analyzed, there is a strong T-cell response to the vaccine that heavily

contribute the life-long protective immunity.<sup>11, 12</sup> Therefore, it is evident that we cannot make protective vaccines against these challenging diseases if we do not engage the entire immune response as a whole.

For the most part, most of our understanding of the formation of immunological memory comes from model antigens and animal models.<sup>13</sup> This is a reasonable approach, and has worked for filling gaps in our knowledge of the cellular and molecular basis of many infections; but in diseases that do not have reliable animal models (such as dengue) or have complex host–pathogen interphases and the immune response is highly multifaceted, the use of animal models with model antigens is rarely predictive of human vaccine responses. Thus, the biggest challenge that we face today is that we do not holistically understand what the immune response in human's looks like during a natural infection or when a successful vaccine is administered. Therefore, there is a tremendous need to develop cutting edge approaches that help us better understand how the immune system functions during an infection to make better vaccines for improving prevention and control.


Understanding several characteristics of human immunology in infected individuals and or vaccines that will ultimately improve the health and well-being of human society in the future. Some of these aspects are molecular signatures of innate immune responses; B-cell responses, antibody secreting cell response; CD4 and CD8 T-cell responses and define correlates of protective immunity in cases of natural infections and successful vaccines. Reproducing these positive characteristics that ultimately result in a successful and protective immune response will allow us to better test and evaluate novel vaccines tested in pre-clinical and clinical studies (Fig. 1).

**Table 1:** Available vaccines.

Small pox	Mumps
Rabies	Pertussis
Diphtheria	Pneumococcal disease
Hepatitis A	Poliomyelitis
Hepatitis B	Rotavirus
Hepatitis E	Rubella
<i>Haemophilus influenza</i>	Tetanus
Human papillomavirus	Tick-borne encephalitis
Japanese encephalitis	Typhoid
Measles	Yellow Fever
Meningococcal meningitis	Tuberculosis
Malaria*	Influenza
Dengue*	*Not used globally

**Table 2:** Hurdles of the complex host–pathogen interphase.

Pathogen-related	Host-related
Immune evasion	Immature immune system
Intracellular life cycle	Elderly
Complex life cycle	Immuno-compromised
Multiple serotypes	Non-communicable/lifestyle diseases
Mutability	Other diseases that affect immune responses
Latency	Immune pathology
Cannot be cultured in vitro	Chronic infections



**Figure 1:** Pathway to the development of a successful vaccine.

Until recently, we could only take a piecemeal approach to understand human immune responses to infections and vaccines. However, recent advances in innovative technologies in human immunology have allowed us to fill some of the gaps in our understanding of the innate and adaptive immune system allowing us to have a more rational approach towards vaccine design, testing, and evaluation. Now, multi-level high-throughput analysis can be performed at both a bulk and a single-cell level to comprehensively profile human immune responses. The advances in multi-parametric flow cytometry have allowed us better quantitate immune phenotype and function of a cell at a single-cell level; advances in systems biology have allowed us to holistically review the entire immune system in its totality in many cell types at a time or even at a single-cell level; advances in next-gen sequencing have permitted us to analyze B- and T-cell receptor repertoires to a single-cell level. Therefore, in the past decade, considerable strides have been made to identify correlates and molecular signatures that predict long-lived memory responses. This information has been very crucial to fill our gaps in understanding of what it takes to make a successful vaccine and helps us in future rational vaccine design, testing, and evaluation.

This review will discuss key technological advances in the light of human immunology that will ultimately allow for rational vaccine designs.

## 2 Understanding the Complex Human Immune Response: New Avenues for Vaccine Development

The challenge for modern vaccines, especially the ones with complicated host–pathogen interactions, is to elicit the multiple steps necessary for

immune activation that will make long-lived protective immune memory. A successful immune response that results in long-lived immunological memory that is protective towards re-challenge from the infecting pathogen begins from the first recognition of the presence of a non-self substance by the innate immune response by a process called pattern recognition. These pattern recognition innate systems recognize and respond to invasion by a various infectious agents by being strategically located at distinct sites within the tissues, cellular spaces, and sub-cellular compartments. Pattern recognition receptors (PPRs) present on innate immune cells such as monocytes, macrophages, neutrophils, and dendritic cells then recognize ‘pathogen associated molecular patterns’ (PAMPs) that could be varied from cell wall components, lipoproteins, lipopolysaccharides, DNA and RNA of bacteria, viruses, protozoan, and fungi.<sup>14–16</sup> The receptor–ligand interactions activate different signaling cascades and elicit downstream immune responses. These downstream signals include chemokines, cytokines, and activation of complement and recruitment of other immune cells, all of which result in local inflammation.<sup>17</sup> The activated innate immune cells carrying the antigen then migrate to local secondary lymphoid tissue to initiate the adaptive immune response. The manner in which the innate cells induce the adaptive immune response has profound implications on the induction of immunological memory.<sup>18</sup>

The formation of immunological memory occurs largely by T- and B-cell responses. Once B cell recognizes a specific antigen, they differentiate into short-lived plasma cells or plasmablasts and secrete antigen-specific antibodies.<sup>19</sup> Some of these B cells that enter the follicles and get CD4

T cell help from the T follicular helpers, become antibody secreting cells that produce high affinity class switched antibodies and also form a pool of memory B cells.<sup>20</sup> On the other hand, both CD4 and CD8 T cells recognize antigens that are processed and presented to them by antigen presenting cells.<sup>21</sup> Upon antigen encounter, CD4 T cells can differentiate into different populations and are categorized based on their functions into Th1, Th2, Th17, TFH, etc.<sup>22</sup> and CD8 T cells differentiate into cytotoxic cells.<sup>23, 24</sup> CD4 T cell help also vital for survival and functional responsiveness of long-lived CD8 T cells.<sup>25, 26</sup> Depending on the orchestration of multiple positive events results in the formation of long-lived immunological memory, whose hallmark is the ability to be rapidly activated upon re-challenge.<sup>27, 28</sup>

For these complex, multi-level pathways to be optimally triggered that ultimately result in long-lived immunological memory responses requires the initiation of an optimal innate immune response that directs the adaptive immune response towards efficient activation in an antigen-specific manner.<sup>29–31</sup> This critical knowledge has allowed us to make huge strides in tailoring vaccines. For example, purified polysaccharide vaccines are poorly immunogenic and do not induce a robust T-cell response.<sup>32, 33</sup> The addition of a protein carrier to such polysaccharide molecules resulted in the activation of innate cells that could then present the antigen to T cells allowing for the development of long-term B- and T-cell immunity. This was only possible because of the knowledge of the workings of an optimal immune response. Such protein-conjugate vaccines have revolutionized our fight against childhood bacterial infections such as *Haemophilus influenzae*, *Neisseria meningitides*, and *Streptococcus pneumoniae*.<sup>34</sup>

### 3 Generating an Optimal Innate Immune Response: In Search of Adjuvants in Vaccine Development

The knowledge of how vital innate immune responses are for a robust adaptive immune response and formation of immunological memory, the role of adjuvant in vaccinology is extremely sought-after. The word ‘adjuvant’ means ‘to help/aid’, because it was originally thought that adjuvants improve vaccine efficiency by prolonging antigen exposure and delivery to the immune system. However, it is now recognized that most efficient adjuvants activate the innate immune pathways either directly or indirectly by inducing other cellular components and

pattern recognition that further activate innate cells.<sup>35</sup> Therefore, there is a huge push for innovative ‘immune potentiators’ or adjuvants that can influence the type, magnitude, and quality of the downstream adaptive T- and B-cell responses. The most important functional criteria are required for a successful adjuvant is overcoming poor immunogenicity, increasing breadth and durability to enhance the outcome of certain vaccines such as subunit vaccines that are weakly immunogenic by themselves as they are designed to include only antigens required for protective immunity and do not have any self-adjuvanting properties that would otherwise be present in whole molecular attenuated or killed vaccines.<sup>36, 37</sup> Due to these features, it also allows for reducing the total antigen quantity that goes into a preparation thus increasing the number of vaccine doses that can be achieved from a finite amount of antigen. Moreover, because they also enhance the innate immune responses by providing the much-needed ‘signal 3’, Signal 3 are cytokines such as IL-12 or type I IFNs that support the expansion and differentiation of T cells. Therefore, in addition to Signal 1 (TCR engagement) and Signal 2 (co-stimulation), an inflammatory stimulus which is the third signal greatly improves the functional quality of an immune response.<sup>38–40</sup> Therefore, incorporation of adjuvants improves immune responses in individuals such as the elderly and infants who have reduced responses to some vaccines.<sup>41</sup> Another favorable aspect of adjuvants is that their effects are short-lived and are not systemic and typically limited to the site of injection and regional lymph nodes.<sup>42</sup>

Aluminum (Alum) was the first adjuvant that was licensed for human use in 1932 and was the only adjuvant in use for almost 70 years. It was extremely successful for vaccines that were protective due to a large antibody response, but was ineffective in situations, where T-cell responses were needed.<sup>43</sup> This was specially true in case of the RTS,S malaria vaccine, where in alum failed as an adjuvant in GSK’s pre-clinical and human challenge studies in the 1980s.<sup>44</sup> It was then that ‘immune stimulating complexes’ (ISCOM) were combined with the RTS,S antigen. ISCOMs are essentially liposome-based adjuvants, wherein the antigen is mixed with saponin, cholesterol, and phospholipid.<sup>45, 46</sup> AS01 is one such liposome adjuvant that has demonstrated increased RTS,S vaccine efficacy in Phase III trials in vaccinated children.<sup>47, 48</sup>

The first vaccine to be licensed for human use that contained an adjuvant that was not alum but an ISCOM was the hepatitis A vaccine in the

mid 1990s.<sup>49</sup> Since then many adjuvants have been included in newer vaccine formulations and enhance both an antibody and T-cell response.<sup>50</sup> The hepatitis B vaccine that now uses AS04 as an adjuvant is a classic example of how adjuvants enhance immune responses in individuals that are immunologically compromised, such as those with end-stage renal disease.<sup>51</sup>

There are several challenges that need to be overcome to find improved adjuvants and formulations. Apart from the understanding of mode of action, we need to ensure that there are no unacceptable side effects, toxicity, and are safe for use in pediatric vaccines.<sup>52</sup> MF59 is one such oil-in-water emulsion that is now licensed in more than 20 countries.<sup>53</sup> After a safety and immunogenicity study in MF59 adjuvanted influenza vaccine in children, it has also been cleared for pediatric vaccine use. Monophosphoryl lipid A (MPL) is a non-toxic derivative of LPS of Salmonella and is a potent inducer of Th1 responses and is now included in the AS04-adjuvanted HPV vaccine and will be the first TLR agonist licensed for human use.<sup>54</sup> Other adjuvants that stimulate the toll-like receptor pathway using TLR 3, 5, and 9 are currently at different phases of clinical trials. Unmethylated CpG that is a TLR9 agonist enhances antigen-specific CD4 and cytotoxic CD8 T-cell responses and the production of pro-inflammatory cytokines.<sup>55</sup> HEPLISAV-B by Dynavax is Hepatitis B vaccine candidate that is currently in Phase 3 clinical trials.<sup>56</sup> Poly I:C binds to TLR 3 and is a potent inducer of Type I

interferons which are imperative for a successful adaptive immune response. Unfortunately, Poly I:C by itself suffered from issues of instability and toxicity. Thus, discovery of its analogue Ampligen was timely and has now been considered as an adjuvant for H5N1 intranasal vaccinations.<sup>57</sup> Another TLR agonist that is in clinical trials for Influenza vaccine is a flagellin-based TLR5 agonist.<sup>58</sup>

We have come a long way, since the approval of Alum as an adjuvant in human vaccines. With better tools and technologies available to dissect the human immune response, following candidate adjuvant administration has allowed us to identify novel combination of adjuvants and formulations that are capable for inducing strong long lasting humoral and cellular immune responses in humans.

Table 3 provides some of the adjuvants currently being tested or are licensed.

There is a constant quest for discovering new adjuvants and this research is happening in parallel to antigen discovery in the field of vaccine development. However, even here, the biggest hurdle has been the gaps in our knowledge on how the immune system responds to adjuvants. The classic example is of alum that has been in use for decades and we still have very little understanding of its mode of action until recently, where in it was demonstrated that Alum introduces host DNA into the cytoplasm of antigen-bearing dendritic cells that results in increased

**Table 3:** Adjuvants, mode of action and status.

Adjuvant	Description	Phase	Refs.
Aluminum	Aluminum salts that increase local inflammation	In use for DPT, IPV, hepatitis A & B, HPV, meningococcal and pneumococcal vaccines	59
Virosomes	Lipid vesicles that increase uptake by APCs	In use for hepatitis and influenza	60
MF59	Squalene. Increases APC recruitment, activation and increases antigen uptake	Seasonal and pandemic influenza	61
CpG	TLR 9 agonist, enhances antibody titer, TH1 and CD8 responses	Phase 3, hepatitis B	56
Poly I:C	TLR 3 agonist, enhances antibody titer, TH1 and CD8 responses	Phase I, cancer immuno-therapies	62
Flagellin	TLR5 agonist, enhances antibody titer, TH1 and CD8 responses	Phase I, cancer immuno-therapies	58
AS01	Monophosphoryl lipid A	Phase 3, RTS,S	63
AS02	Squalene	Phase 3, pneumococcal vaccine	64
AS03	Alpha-tocopherol, Squalene and surfactant polysorbate 80 promotes local production of cytokines	Pandemic influenza	65
AS04	3-deacyl-monophosphoryl lipid A derived from LPS of Salmonella Minnesota. Stimulates TLR4	In use for hepatitis B and HPV	66

MHC Class II expression and thereby antigen presentation.<sup>67</sup>

Since an optimal immune response not only requires cellular factors but requires multiple soluble signals in the form of cytokines and chemokines. Based on the type of cytokine or chemokine, secreted results in target cell activation, proliferation, differentiation, migration, and mounting antigen-specific responses. Therefore, using new technologies such as xMAP luminex that allow us to analyze almost 500 unique markers has given us predictive value of the type of immune response that will be generated in presence of a particular adjuvant.<sup>68</sup>

As advances are made in human immunology, we hope that we will have a deeper understanding of the mode of action of adjuvants on the innate and adaptive immune response and fast-track towards a rationale vaccine design for diseases such as dengue, HIV, etc.

Cutting edge human immunology research on successful vaccines such as the yellow fever vaccine have allowed us to get a glimpse into what the appropriate quality of a successful immune response looks like.<sup>11, 12, 69</sup> Moreover, progress in genomics has allowed us to process large amounts of data in a high-throughput manner from human blood samples and use sophisticated systems biology approaches to identify molecular signatures and immunological correlates of protection.<sup>70</sup> Refinement of technologies such as flow cytometry and addition of new dimensions to classic flow-cytometry analysis has opened our avenues to perform improved analysis on human immune responses and are discussed in the sections below.

#### 4 The Power of Multi-parametric Flow Cytometry for Human Immunophenotyping: Implications for Vaccine Design

One of the most successful technologies that revolutionized the analysis of human immune responses is multi-color and multi-dimensional flow cytometry. This innovative technique uses antigen-specific antibodies typically coupled to a fluorochrome to detect expression of surface markers and intracellular proteins. One of the major advantages of this technique is that it is high-throughput and allows for the analysis of approximately 10,000 cells/s to sorting individual cells to analyze at a single-cell level. The number of parameters that this technology can accommodate depends on the number of lasers and filters that the machine used can incorporate, for e.g., a machine with 4 lasers and 5 filters per laser

can determine up to 20 parameters simultaneously. Flow cytometry is the mainstay of vaccine research and development because it has for the first time allowed us to monitor multiple phenotypic and functional changes during complex immune responses.

Because we now know that heavy reliance on generation of an antibody-based protective immunity may not always be successful, there is a renewed interest in understanding T-cell responses that can be channeled in a vaccine design. Flow cytometry allows us to do this. Studies with yellow fever vaccine is classic example due to which we now a lot more about CD8 T-cell responses in successful vaccines and gives us immune correlates of protection.<sup>11, 12</sup>

Intracellular cytokine assays by flow cytometry have permitted us to study the ability of immune cells to make multiple cytokines ex vivo in response to a vaccine challenge. Due to this powerful technique, researchers could find prospective evidence of correlates to protection in CD4 T-cell responses for an intracellular parasite *Leishmania major*.<sup>71</sup>

Another important aspect of effector CD8 T cells is that they are cytotoxic and have the ability to kill infected cells. To do this, CD8 T cells degranulate which can be studied by CD107a (LAMP1) expression by flow cytometry. This protein is normally expressed in the internal granular membranes and is transiently expressed on the cell surface when CD8 T cells undergo degranulation and the granule membrane merges with the cell membrane. Addition of the anti-CD107a fluorescently labeled antibody to the culture at the time of stimulation allows us to gauge cytotoxic CD8 T-cell responses by flow cytometry.<sup>72</sup> Simultaneous measurement of other cytotoxic molecules ex vivo such as Perforin and Granzymes allows researchers to gauge the level of cytotoxic T-cell responses after natural infections and vaccinations more accurately.<sup>73</sup>

In addition, when naïve cells encounter cognate antigen during vaccination or natural infections, they undergo massive proliferation to form effector cells. Flow cytometry has transformed our ability to study this proliferation trait. Dyes such as carboxyfluorescein succinimidyl ester (CFSE), PKH-26 or DNA labeling by bromodeoxyuridine (BrdU) that can be analyzed on a flow cytometer have completely eliminated our need to use radioactive thymidine.<sup>74</sup> Combining lymphoproliferation with phenotype and functional assays has given us the power to analyze the evolution of an immune response in context of time.


Cytotoxicity can also be measured by *in vitro* killing assays that use effector CD8 T cells co-cultured with peptide-labeled target cells. Originally developed as an radioactivity based assay, where in the release of radioactive chromium from dying target cells was measured.<sup>75</sup> However, these assays were not very sensitive and more importantly the quality of the T cells could not be assessed. Due to flow cytometry, it is now possible and safer to use fixable live dead stains or CFSE labeled target cells whose gain or loss respectively can be measured along with qualitative measurement of the effector cells.<sup>76</sup> Correspondingly, other functional assays such as activation of caspases,<sup>77</sup> TCR signaling<sup>78</sup> and phosphorylation of proteins<sup>79</sup> can be analyzed reproducibly with a flow cytometer. Similarly, other important correlates of protection such as ‘antibody dependent cell mediated cytotoxicity’ (ADCC) or activation of complement pathway can also be tailored for flow-cytometry analysis.<sup>80</sup> This has been used extensively to analyze the therapeutic potential of anti-cancer antibodies through their ability to initiate ADCC or cell mediated lympholysis (CML).<sup>81</sup> Researchers have also analyzed the role of granulocyte phagocytosis in pneumococcus vaccinations as a correlate of protection using flow cytometry.<sup>82, 83</sup> Finally, for analysis of T-cell functionality, intracellular cytokine assays by flow cytometry are a goldmine that have given us the ability to analyze immune cells making multiple cytokines *ex vivo* in response to a vaccine challenge or infection.<sup>84, 85</sup>

Thus, multi-parametric flow cytometry has revolutionized vaccine research because it has provided us with the unique ability to analyze different parameters such as proliferation, phenotype, cytokine production, intracellular protein expression, phosphorylation, etc. in a high-throughput manner but continuing to retain the ability of single-cell analysis. This technology has single-handedly revolutionized design, testing and evaluation of candidate vaccines.

Almost all successful vaccines induce a potent and long-lived serological response.<sup>86</sup> Recently, a population of antibody secreting B cells were identified that transiently appears the blood of subjects that are infected or vaccinated. These plasmablasts, are mostly antigen-specific and make antibodies only to the current infection or vaccination.<sup>69, 87, 88</sup> Human immune phenotyping allowed for identification of these cells by their expression of unique surface markers. Studies performed with yellow fever virus vaccine<sup>69</sup>; influenza vaccine<sup>87, 89</sup>; tetanus vaccine<sup>90</sup> and dengue infections<sup>91</sup> all identified these cells appearing during the acute phase of the antigen-specific immune response. Therefore, this transient nature of the appearance of plasmablasts in the periphery is now a key parameter that can be used to gauge the responsiveness of subjects to any vaccine. In addition, apart from analysis of serum antibody titers and neutralizing ability of the antibodies, responsiveness to new vaccines can be judged based on burst of the plasmablast response and their functionality and



**Figure 2:** Flow-cytometry-based technologies are at the center stage of vaccine research and discovery.



**Figure 3:** MHC tetramer technology allows us to accurately detect and track antigen-specific T cells.

holds predictive value during vaccine testing and evaluation.

Because flow cytometry is restricted to the number of fluorochromes, lasers and filter combination another advanced technique that has made multiple measurements of complex immune responses feasible is cytometry by time-of-flight (CyTOF). This innovative technique uses advantages of flow cytometry to perform single-cell analysis and combines it with mass cytometry.<sup>68, 92</sup> This is achieved by not using fluorochrome labeled antibodies but heavy metal tags allowing 45–50 measurements at a time with very little spectral overlap. Therefore, using CyTOF multi-parametric vaccine responses can be measured to characterize phenotype, function, antigen-specificity, signaling, phosphorylation, proliferation, cell cycle phases, and numbers in a single stain which is invaluable to vaccine research where in multi-dimensional analysis is needed to identify novel cellular functions that mark correlates of protective immunity<sup>93</sup> (Fig. 2).

### 5 Finding Needles in a Haystack: Tetramer Technology

After initial encounter with antigen and formation of effector cells, only a very small number of immune cells survive and form memory cells that typically homes to the bone marrow<sup>28, 94</sup>. To find those small frequencies of memory cells that may be circulating in the peripheral blood after vaccination or a natural infection requires very sensitive and high-throughput methods. One of the cutting edge technologies that has facilitated this analysis is the ability to stain and track antigen-specific T cells that are responding to a particular

peptide/antigen of interest. This innovation is the MHC tetramer technology that was first pioneered in 1996 when soluble MHC–peptide complexes were made that were fluorescently tagged and thus could be detected by a flow cytometer<sup>95</sup>. Since the development of this technology, researchers have had the power to identify, visualize, enumerate, phenotype and isolate antigen-specific T cells<sup>96–100</sup>. The technology exploits the presence of alpha–beta T-cell receptors on the surface of T cells that are specific to the molecular complex of a particular MHC bound peptide. Biotinylation followed by conjugation to a fluorescent streptavidin allows the MHC–peptide monomers to get tetramerized that increases specific binding and decreases internalization of the TCR<sup>101</sup> (Fig. 3). Tetramer labeled cells can be analyzed for further phenotypic and functional characteristics because the staining can be combined with both surface and intracellular staining protocols. Therefore, the use of both MHC Class I and II tetramers has allowed researchers to monitor antigen-specific T cells generated during vaccine responses and in natural infections. Most importantly, because tetramer staining relies on the MHC–peptide–TCR complex, it is very specific and thus few numbers of memory cells can also be enumerated months after vaccinations or natural infections.<sup>11, 12</sup> The key ingredients required for tetramers is the knowledge of the antigenic regions or peptides that the T cells may be responding to in context of its HLA. This is typically done through a process called epitope mapping. Recently, using biotin conjugated–tetramerized proteins have allowed for the



detection of small numbers of circulating memory B cells after tetanus vaccination.<sup>102</sup>

The key to making good memory cells after vaccination is to identify the antigenic regions that result in a strong effector and memory response. In case the immuno-dominant epitope is hidden in the natural conformation of the protein, using whole protein in vaccine formulations result in sub-optimal immunity. Therefore, for an intelligent vaccine design, it is important to identify and incorporate the immuno-dominant regions in a candidate antigen. Identification of regions or epitopes that generate maximal immune responses has been possible by the process of epitope mapping.

## 6 Immuno-dominant Epitope Discovery by High-Throughput Mapping

Identification immuno-dominant epitopes is required not only to identify antigen-specific cells through tetramer technology, but more importantly to ensure that these epitopes are accessible in the candidate vaccine for an optimal immune response. Thus, mapping of immuno-dominant epitopes is crucial for T-cell-based vaccine development. This process was historically challenging because one needed to identify regions of T-cell reactivity across entire pathogen proteomes. However, with improved tool and technologies to sequence entire genomes it has become a lot more feasible to generate synthetic overlapping peptides that span the entire proteome or candidate protein(s) of a pathogen. Utilizing these in the form of peptide matrixes such that two pools contain only a single peptide in common made this method more high-throughput.<sup>103, 104</sup> Such overlapping peptide screens have been used for both T cell and antibody mapping and thus allow dissection of both B- and T-cell responses in infected subjects or vaccinees and thus allow for predicting what sequences must be present in the candidate vaccine to ensure a robust T-cell response.<sup>105, 106</sup> Similar approaches can also be used to identify linear epitopes that induce humoral or antibody responses. In fact, screening of human sera samples, or purified antibodies has been made extremely rapid and high-throughput by modern methods that allow us to globally profile antibody responses. These systems use highly purified whole protein or peptide blotted on microarray chips and represents either the entire pathogen proteome or certain sections of it.<sup>107–110</sup> The diversity and breakdown of the antibody responses can then rapidly measured to select for antigens or proteins that have the maximum


immune responses and can be further explored as vaccine candidates.

## 7 Antibody and T-Cell Repertoire Analysis for Vaccine Testing and Evaluation

The ultimate goal of vaccines is to generate an adaptive immune response capable of detecting and rapidly eliminating the pathogen upon encounter. To achieve this, both T- and B-cell responses must be generated in diverse configurations that allow for the detection of vast number of antigens. This is called the repertoire of the immune response. Another cutting edge new technology that has deeply impacted vaccine design and research is nucleic acid sequencing. Recent advances made that allow for high-throughput next generation sequencing of T- and B-cell repertoires have allowed us to analyze the diversity, clonal expansion, immune variability of both B and T cells in context of a vaccine responses.<sup>111–113</sup> A recent development that has extended NGSs usefulness in vaccine responses further is the ability to sequence single responding T- and B-cell ex vivo.<sup>114</sup> Individual cells are sorted from human blood such that every single cell is immediately lysed and the TCR or Ig chains are amplified. After amplification all products from the single cell are ligated to a 'barcode' that allows all products from the same cell to be re-grouped informatically at a later stage and thus complete information of heavy and light chains from a single antibody secreting cell or plasmablast or alpha/beta TCRs of effector T cells can be reconstructed.<sup>115</sup> Thus, NGS is becoming a vital technology in vaccine research and analysis with the ultimate goal to identify signals, factors or pathways that result in a protective immune response with the idea to potentially specifically enhance those protective responses during a vaccination regime.<sup>105, 116</sup>

## 8 Antibody Therapies: An Alternative to Traditional Vaccination Approaches?

There are instances especially in cases of sudden outbreaks in naïve unexposed populations that administration of vaccines may be too little and too late to help the population. In such cases, and in absence of drugs that can help infected individuals, therapeutic antibody treatments are a promising route. Moreover, though antigen discovery that induces broadly neutralizing antibodies has been the goal of almost all vaccine discovery efforts, it is not always possible to reconfigure the epitopes to which the most neutralizing antibody



**Figure 4:** High-throughput production of human monoclonal antibodies.

responses are directly. This is specifically true in cases if the neutralizing antibody response is directed towards a conformational epitope that requires the native antigen to be in a 3D confirmation that cannot be achieved in a recombinant vaccine. It also becomes challenging in case the target pathogen has multiple serotypes/genotypes that have to be incorporated into the vaccine to generate the optimal response. In such cases, it is judicious to reverse the approach and generate a class of broadly neutralizing by isolating the plasmablasts that are making the antibody of interest. Such passive immunization techniques can be traced back to the early twentieth century where in sera from infected and recovered humans was used to provide protective immunity to naïve-uninfected subjects.<sup>117</sup> This serum therapy was gradually replaced by the use of antibodies purified from pooled sera for intravenous immune globulin (IVIG) and has had a major impact in the treatment of many immunological, neurological, dermatological illnesses, etc.<sup>118</sup> This method soon took a back seat in 1975 when a method to generate large quantities of murine monoclonal antibodies was discovered.<sup>119</sup> However, due to the lack of myeloma fusion partners that could be used for human B cells, the use of this technique for immune prophylaxis was minimal. Several methods were then discovered and one of the most successful ones were to use phage display libraries, where VH and VL variable regions from immune, vaccinated, or naturally infected and recovered individuals were cloned.<sup>120–122</sup> However, it was because the heavy and light chain pairing was random and did not reflect the true antibody repertoire that was generated in vivo the use of these antibodies therapeutically was minimal.


The game changer technology that was first reported in 2009 was making human monoclonal antibodies directly from circulating antibody secreting cells or memory B-cell ex vivo. This was rapid and high-throughput where in heavy and light chains were cloned from the same single plasmablast cell sorted ex vivo and produced

in a standard 293T culture system. The antibody secreting cells were identified by surface marker expression or antigen bait, and then sorted into single cells using a flow cytometer. The heavy and light chains of the Fab fragment were then cloned from the same cell to generate clones of the antibodies that were being originally produced in vivo by that plasmablast.<sup>123, 124</sup> This method is highly throughput, since the cells are sorted in 96 well plates and can result in hundreds of potential antibodies in a short duration that can be then tested for their functional ability (Fig. 4).

Moreover, since these antibodies are completely human they are potentially safer to be used as immuno-therapies of prophylaxis against infections. Lastly, since the technology is also high-throughput, monoclonal can be made in a very short duration of time and thus potentially be available to treat or prevent infections with the period of an epidemic with a novel pathogen.

Many other novel technologies are currently under investigation in the field of vaccine research and development. Advances in the state-of-the-art techniques such as X-ray crystallography, Nuclear Magnetic Resonance (NMR) and cryo electron microscopy that won the nobel prize for chemistry this year, have paved the way for structural vaccinology.<sup>3, 125, 126</sup> These cutting edge techniques allow a deeper characterization of antigenic regions and neutralizing epitopes of pathogens by crystal structures is a revolutionary technique that allows rationale and intelligent design of vaccines for pathogens that are inherently difficult to manipulate by classical biochemical methods.

Therefore, the combination of human immunology, structural biology and bioinformatics is allowing us to make major strides in filling the gaps in our understanding of immune responses to natural infections and vaccines. These powerful techniques are now providing us with strategies for rationale vaccine design that generate broad and effective immunity to pathogens that have historically proven to be challenging. This multi-pronged approach to understand the complexities



**Figure 5:** Different arms of the immune system targeted in vaccine discovery.

of the immune system will eventually allow us to design vaccines that will contribute to a significantly long and disease free life.

## 9 Conclusions

Our understanding of human immune responses is increasing at an unprecedented scale. Cutting edge new technologies are allowing us to disregard a piecemeal approach and analyze human immune responses in a comprehensive and cohesive manner. Innovative approaches to analyze immune cell phenotype, genotype, function, and associated soluble factors have provided us with a new hope for making vaccines against diseases that have been historically impossible.

Analysis of the complexity of the immune response using multi-parametric innovative approaches is the most likely be key to in discovery of novel vaccines and therapeutics. The advent of these new technologies has allowed for advances in human immunology and development of vaccines that would have not been possible otherwise. Bringing together all the

knowledge that we gain from different angles of the human immune response, we can hope to make novel and improved vaccines and therapies for diseases such as HIV, Dengue, Chikungunya that are urgently needed for improvement of health and well-being of society (Fig. 5).

## Funding

This work was supported by National Institutes of Health grant ICIDRIU01AI115651 and Indo-US VAP BT/MB/Indo-US/VAP/06/2013.

Received: 10 October 2017 Accepted: 7 February 2018  
Published online: 15 March 2018

## References

1. Walter A, Orenstein RA (2017) Simply put: vaccination saves lives. *PNAS* 114(6):4031–4033
2. Thucydides (1989) *The history of the Peloponnesian war*. University of Chicago Press, Chicago
3. De Gregorio E, Rappuoli R (2014) From empiricism to rational design: a personal perspective of the

- evolution of vaccine development. *Nat Rev Immunol* 14(7):505–514
4. Needham J (1980) China and the origins of immunology. *East Horiz* 19(1):6–12
  5. Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. *Proceedings (Bayl Univ Med Cent)* 18(1):21–25
  6. Willis NJ (1997) Edward Jenner and the eradication of smallpox. *Scott Med J* 42(4):118–121
  7. Rappuoli R (2014) Inner workings: 1885, the first rabies vaccination in humans. *Proc Natl Acad Sci USA* 111(34):12273
  8. Kollmann TR, Marchant A (2016) Towards predicting protective vaccine responses in the very young. *Trends Immunol* 37(8):523–534
  9. Effros RB (2001) Ageing and the immune system. *Novartis Found Symp* 235:130–139 (**discussion 139–45, 146–9**)
  10. Pozzilli P et al (1986) The immune response to influenza vaccination in diabetic patients. *Diabetologia* 29(12):850–854
  11. Ahmed R, Akondy RS (2011) Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. *Immunol Cell Biol* 89(3):340–345
  12. Akondy RS et al (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. *J Immunol* 183(12):7919–7930
  13. Zhou X et al (2012) Role of lymphocytic choriomeningitis virus (LCMV) in understanding viral immunology: past, present and future. *Viruses* 4(11):2650–2669
  14. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. *Annu Rev Immunol* 20:197–216
  15. Kawai T, Akira S (2007) TLR signaling. *Semin Immunol* 19(1):24–32
  16. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol* 11(5):373–384
  17. Kumar H, Kawai T, Akira S (2009) Toll-like receptors and innate immunity. *Biochem Biophys Res Commun* 388(4):621–625
  18. Gayed PM (2011) Toward a modern synthesis of immunity: Charles A. Janeway Jr. and the immunologist's dirty little secret. *Yale J Biol Med* 84(2):131–138
  19. Wrammert J, Ahmed R (2008) Maintenance of serological memory. *Biol Chem* 389(5):537–539
  20. Crotty S (2015) A brief history of T cell help to B cells. *Nat Rev Immunol* 15(3):185–189
  21. Wieczorek M et al (2017) Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. *Front Immunol* 8:292
  22. Zhou L, Chong MM, Littman DR (2009) Plasticity of CD4+ T cell lineage differentiation. *Immunity* 30(5):646–655
  23. Buchholz VR, Graf P, Busch DH (2013) The smallest unit: effector and memory CD8(+) T cell differentiation on the single cell level. *Front Immunol* 4:31
  24. Wherry EJ, Ahmed R (2004) Memory CD8 T-cell differentiation during viral infection. *J Virol* 78(11):5535–5545
  25. Khanolkar A, Badovinac VP, Harty JT (2007) CD8 T cell memory development: CD4 T cell help is appreciated. *Immunol Res* 39(1–3):94–104
  26. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. *Science* 300(5617):337–339
  27. Cui W, Kaech SM (2010) Generation of effector CD8+ T cells and their conversion to memory T cells. *Immunol Rev* 236:151–166
  28. Kaech SM et al (2003) Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. *Nat Immunol* 4(12):1191–1198
  29. Cui W et al (2011) An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. *Immunity* 35(5):792–805
  30. Iwasaki A, Medzhitov R (2015) Control of adaptive immunity by the innate immune system. *Nat Immunol* 16(4):343–353
  31. Jain A, Pasare C (2017) Innate control of adaptive immunity: beyond the three-signal paradigm. *J Immunol* 198(10):3791–3800
  32. Barrett DJ (1985) Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants. *Adv Pediatr* 32:139–158
  33. Klein Klouwenberg P, Bont L (2008) Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. *Clin Dev Immunol* 2008:628963
  34. Maiden MC (2013) The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis? *Philos Trans R Soc Lond B Biol Sci* 368(1623):20120147
  35. McKee AS, Marrack P (2017) Old and new adjuvants. *Curr Opin Immunol* 47:44–51
  36. Douglas AD et al (2010) Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against *Plasmodium falciparum* MSP1. *Vaccine* 28(44):7167–7178
  37. Noad R, Roy P (2003) Virus-like particles as immunogens. *Trends Microbiol* 11(9):438–444
  38. Awate S, Babiuk LA, Mutwiri G (2013) Mechanisms of action of adjuvants. *Front Immunol* 4:114
  39. Curtsinger JM, Mescher MF (2010) Inflammatory cytokines as a third signal for T cell activation. *Curr Opin Immunol* 22(3):333–340
  40. Mescher MF et al (2006) Signals required for programming effector and memory development by CD8+ T cells. *Immunol Rev* 211:81–92
  41. Di Pasquale A et al (2015) Vaccine adjuvants: from 1920 to 2015 and beyond. *Vaccines (Basel)* 3(2):320–343

42. Didierlaurent AM et al (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. *J Immunol* 183(10):6186–6197
43. Kool M, Fierens K, Lambrecht BN (2012) Alum adjuvant: some of the tricks of the oldest adjuvant. *J Med Microbiol* 61(Pt 7):927–934
44. Ballou WR, Cahill CP (2007) Two decades of commitment to malaria vaccine development: Glaxo-SmithKline Biologicals. *Am J Trop Med Hyg* 77(6 Suppl):289–295
45. Lovgren Bengtsson K, Morein B, Osterhaus AD (2011) ISCOM technology-based matrix M adjuvant: success in future vaccines relies on formulation. *Expert Rev Vaccines* 10(4):401–403
46. Wilson NS et al (2012) ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. *Immunol Cell Biol* 90(5):540–552
47. Kester KE et al (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. *J Infect Dis* 200(3):337–346
48. Leroux-Roels G et al (2014) Evaluation of the immune response to RTS, S/AS01 and RTS, S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naive adults. *Hum Vaccin Immunother* 10(8):2211–2219
49. Bovier PA (2008) Epaxal: a virosomal vaccine to prevent hepatitis A infection. *Expert Rev Vaccines* 7(8):1141–1150
50. Fox CB et al (2013) Working together: interactions between vaccine antigens and adjuvants. *Ther Adv Vaccines* 1(1):7–20
51. Somi MH, Hajipour B (2012) Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants. *ISRN Gastroenterol* 2012:960413
52. Wadman M (2005) Race is on for flu vaccine. *Nature* 438(7064):23
53. Baldrige JR, Crane RT (1999) Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. *Methods* 19(1):103–107
54. Garcon N et al (2011) Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. *BioDrugs* 25(4):217–226
55. Bevan MJ (2004) Helping the CD8(+) T-cell response. *Nat Rev Immunol* 4(8):595–602
56. Sung JJ, Lik-Yuen H (2006) HBV-ISS (Dynavax). *Curr Opin Mol Ther* 8(2):150–155
57. Martins KA, Bavari S, Salazar AM (2015) Vaccine adjuvant uses of poly-IC and derivatives. *Expert Rev Vaccines* 14(3):447–459
58. Kim JR et al (2015) Inclusion of flagellin during vaccination against influenza enhances recall responses in nonhuman primate neonates. *J Virol* 89(14):7291–7303
59. Lindblad EB (2004) Aluminium compounds for use in vaccines. *Immunol Cell Biol* 82(5):497–505
60. Gluck R (1999) Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). *Vaccine* 17(13–14):1782–1787
61. Tsai TF (2011) MF59 adjuvanted seasonal and pandemic influenza vaccines. *Yakugaku Zasshi* 131(12):1733–1741
62. Ammi R et al (2015) Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. *Pharmacol Ther* 146:120–131
63. RTS, SCTP et al (2012) A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. *N Engl J Med* 367(24):2284–2295
64. Leroux-Roels I et al (2015) Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. *Vaccine* 33(4):577–584
65. Nolan T et al (2014) Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. *J Infect Dis* 210(4):545–557
66. Pedersen C et al (2012) Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. *J Adolesc Health* 50(1):38–46
67. McKee AS et al (2013) Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. *Proc Natl Acad Sci USA* 110(12):E1122–E1131
68. Furman D, Davis MM (2015) New approaches to understanding the immune response to vaccination and infection. *Vaccine* 33(40):5271–5281
69. Wrammert J et al (2009) Human immune memory to yellow fever and smallpox vaccination. *J Clin Immunol* 29(2):151–157
70. Nakaya HI, Pulendran B (2015) Vaccinology in the era of high-throughput biology. *Philos Trans R Soc Lond B Biol Sci* 370(1671):20140146
71. Darrah PA et al (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against *Leishmania major*. *Nat Med* 13(7):843–850
72. Betts MR, Koup RA (2004) Detection of T-cell degranulation: CD107a and b. *Methods Cell Biol* 75:497–512
73. Betts MR et al (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. *J Immunol Methods* 281(1–2):65–78
74. Sheehy ME et al (2001) A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. *J Immunol Methods* 249(1–2):99–110
75. Fossati G, Holden HT, Herberman RB (1975) Evaluation of the cell-mediated immune response to murine

- sarcoma virus by (<sup>125</sup>I)iododeoxyuridine assay and comparison with chromium 51 and microcytotoxicity assays. *Cancer Res* 35(9):2600–2608
76. Peretto SP et al (2010) Amine-reactive dyes for dead cell discrimination in fixed samples. *Curr Protoc Cytom Chapter 9:Unit 9.34*
  77. Liu L et al (2002) Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. *Nat Med* 8(2):185–189
  78. Hanschen M et al (2012) Phospho-flow cytometry based analysis of differences in T cell receptor signaling between regulatory T cells and CD4+ T cells. *J Immunol Methods* 376(1–2):1–12
  79. Krutzik PO et al (2004) Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. *Clin Immunol* 110(3):206–221
  80. Gillissen MA et al (2016) The modified FACS calcein AM retention assay: a high throughput flow cytometer based method to measure cytotoxicity. *J Immunol Methods* 434:16–23
  81. La Muraglia GM 2nd et al (2015) A novel approach to measuring cell-mediated lympholysis using quantitative flow and imaging cytometry. *J Immunol Methods* 427:85–93
  82. Martinez JE et al (2006) Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to *Streptococcus pneumoniae*. *Clin Vaccine Immunol* 13(4):459–466
  83. Martinez JE et al (1999) A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine. *Clin Diagn Lab Immunol* 6(4):581–586
  84. Saade F, Gorski SA, Petrovsky N (2012) Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. *Expert Rev Vaccines* 11(12):1459–1470
  85. Smith SG et al (2015) Intracellular cytokine staining and flow cytometry: considerations for application in clinical trials of novel tuberculosis vaccines. *PLoS ONE* 10(9):e0138042
  86. Crotty S, Ahmed R (2004) Immunological memory in humans. *Semin Immunol* 16(3):197–203
  87. Ellebedy AH et al (2016) Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. *Nat Immunol* 17(10):1226–1234
  88. Magnani DM et al (2017) Potent plasmablast-derived antibodies elicited by the NIH dengue vaccine. *J Virol.* <https://doi.org/10.1128/JVI.00867-17>
  89. He XS et al (2011) Plasmablast-derived polyclonal antibody response after influenza vaccination. *J Immunol Methods* 365(1–2):67–75
  90. Qian Y et al (2010) Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data. *Cytom B Clin Cytom* 78(Suppl 1):S69–S82
  91. Wrämmert J et al (2012) Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. *J Virol* 86(6):2911–2918
  92. Maecker HT, McCoy JP, Nussenblatt R (2012) Standardizing immunophenotyping for the Human Immunology Project. *Nat Rev Immunol* 12(3):191–200
  93. Chen G, Weng NP (2012) Analyzing the phenotypic and functional complexity of lymphocytes using CyTOF (cytometry by time-of-flight). *Cell Mol Immunol* 9(4):322–323
  94. Masopust D et al (2004) The role of programming in memory T-cell development. *Curr Opin Immunol* 16(2):217–225
  95. Altman JD et al (1996) Phenotypic analysis of antigen-specific T lymphocytes. *Science* 274(5284):94–96
  96. Altman JD, Davis MM (2016) MHC-peptide tetramers to visualize antigen-specific T cells. *Curr Protoc Immunol* 115:17.3.1–17.3.44
  97. Day CL et al (2003) Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. *J Clin Invest* 112(6):831–842
  98. Meidenbauer N, Hoffmann TK, Donnenberg AD (2003) Direct visualization of antigen-specific T cells using peptide-MHC-class I tetrameric complexes. *Methods* 31(2):160–171
  99. Nepom GT (2012) MHC class II tetramers. *J Immunol* 188(6):2477–2482
  100. Stock A, Cerundolo V (2009) Analysis of frequency and phenotype of antigen-specific T cells. *Methods Mol Biol* 514:1–14
  101. Davis MM, Altman JD, Newell EW (2011) Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. *Nat Rev Immunol* 11(8):551–558
  102. Franz B et al (2011) Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. *Blood* 118(2):348–357
  103. Fiore-Gartland A et al (2016) Pooled-peptide epitope mapping strategies are efficient and highly sensitive: an evaluation of methods for identifying human T cell epitope specificities in large-scale HIV vaccine efficacy trials. *PLoS ONE* 11(2):e0147812
  104. Precopio ML et al (2008) Optimizing peptide matrices for identifying T-cell antigens. *Cytometry A* 73(11):1071–1078
  105. Price JV et al (2013) Characterization of influenza vaccine immunogenicity using influenza antigen microarrays. *PLoS ONE* 8(5):e64555
  106. Zhang C et al (2017) Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. *PLoS ONE* 12(2):e0171217

107. Chen CW, Chang CY (2017) Peptide scanning-assisted identification of a monoclonal antibody-recognized linear B-cell epitope. *J Vis Exp*. <https://doi.org/10.3791/55417>
108. Gaze S et al (2014) An immunomics approach to schistosoma antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas. *PLoS Pathog* 10(3):e1004033
109. Lu F et al (2014) Profiling the humoral immune responses to *Plasmodium vivax* infection and identification of candidate immunogenic rhoptry-associated membrane antigen (RAMA). *J Proteom* 102:66–82
110. Potocnakova L, Bhide M, Pulzova LB (2016) An introduction to B-cell epitope mapping and in silico epitope prediction. *J Immunol Res* 2016:6760830
111. Boyd SD, Crowe JE Jr (2016) Deep sequencing and human antibody repertoire analysis. *Curr Opin Immunol* 40:103–109
112. Gourley TS et al (2004) Generation and maintenance of immunological memory. *Semin Immunol* 16(5):323–333
113. Robinson WH (2015) Sequencing the functional antibody repertoire—diagnostic and therapeutic discovery. *Nat Rev Rheumatol* 11(3):171–182
114. Tan YC et al (2014) Barcode-enabled sequencing of plasmablast antibody repertoires in rheumatoid arthritis. *Arthritis Rheumatol* 66(10):2706–2715
115. Han A et al (2014) Linking T-cell receptor sequence to functional phenotype at the single-cell level. *Nat Biotechnol* 32(7):684–692
116. Legutki JB et al (2010) A general method for characterization of humoral immunity induced by a vaccine or infection. *Vaccine* 28(28):4529–4537
117. Winau F, Westphal O, Winau R (2004) Paul Ehrlich—in search of the magic bullet. *Microbes Infect* 6(8):786–789
118. Stangel M, Pul R (2006) Basic principles of intravenous immunoglobulin (IVIg) treatment. *J Neurol* 253(Suppl 5):V18–V24
119. Kohler G, Milstein C (2005) Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. *J Immunol* 174(5):2453–2455
120. Kang AS et al (1991) Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. *Proc Natl Acad Sci USA* 88(10):4363–4366
121. McCafferty J et al (1990) Phage antibodies: filamentous phage displaying antibody variable domains. *Nature* 348(6301):552–554
122. Szardenings M, Collins J (1990) A phasmid optimised for protein design projects: pMAMPE. *Gene* 94(1):1–7
123. Smith K et al (2009) Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. *Nat Protoc* 4(3):372–384
124. Wrammert J et al (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J Exp Med* 208(1):181–193
125. Liljeroos L et al (2015) Structural and computational biology in the design of immunogenic vaccine antigens. *J Immunol Res* 2015:156241
126. Malito E, Carfi A, Bottomley MJ (2015) Protein crystallography in vaccine research and development. *Int J Mol Sci* 16(6):13106–13140



**Anmol Chandele** is an Assistant Professor at the ICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi. My lab is a unique partnership between Emory Vaccine Center, Atlanta, USA and ICGEB, New

Delhi. She has worked extensively in the field of 'immunological memory'. My earlier studies were focused on the genetic components that dictate formation of immunological memory during acute infections. She has harnessed my knowledge gained with mouse models of infection and put in considerable effort to gain a better understanding of human immune responses to infectious diseases that are of

public health importance in India with special emphasis on disease such as dengue and chikungunya virus infections. While being actively involved in developing and establishing *cutting edge* state-of-the-art immunology platforms for quantitating innate and antigen-specific effector B- and T-cell responses in humans, I am also teaching and training both graduate-level and postdoctoral-level students in these new state-of-the-art technologies, which is critical for capacity building in India. The complete list of my publications can be found on: <http://www.ncbi.nlm.nih.gov/pubmed/?term=Chandele+A>.